Search

• Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone

  Media

  Interim results from Part 1 of the RUBY clinical trial in primary advanced or recurrent endometrial cancer.

  https://www.gsk.com/en-gb/media/press-releases/phase-iii-ruby-clinical-trial-demonstrates-potential-of-jemperli-plus-chemotherapy-to-redefine-the-treatment-of-primary-advanced-or-recurrent-endometrial-cancer/

  First published: 27 March 2023

• Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia

  Media

  Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.

  https://www.gsk.com/en-gb/media/press-releases/ojjaara-momelotinib-approved-in-the-us-as-the-first-and-only-treatment-indicated-for-myelofibrosis-patients-with-anaemia/

  First published: 15 September 2023

• GSK highlights new data in non-small cell lung cancer and endometrial cancer at the European Society for Medical Oncology (ESMO) Congress 2023, reinforcing potential of Jemperli (dostarlimab) as a backbone immuno-oncology therapy

  Media

  Late-breaking data from head-to-head PERLA trial shows favourable numerical trend in overall survival (OS) results

  https://www.gsk.com/en-gb/media/press-releases/gsk-highlights-new-data-in-non-small-cell-lung-cancer-and-endometrial-cancer-at-esmo/

  First published: 17 October 2023

• New global survey finds widespread misunderstandings about shingles despite its lifetime prevalence

  Media

  A new GSK survey shows a large number of adults do not understand how shingles may be triggered.

  https://www.gsk.com/en-gb/media/press-releases/new-global-survey-finds-widespread-misunderstandings-about-shingles-despite-its-lifetime-prevalence/

  First published: 30 November 2023

• GSK’s Omjjara (momelotinib) approved in Japan for treatment of myelofibrosis

  Media

  Omjjara approved for use in both newly diagnosed or previously treated myelofibrosis patients.

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-omjjara-momelotinib-approved-in-japan-for-treatment-of-myelofibrosis/

  First published: 24 June 2024

• ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV

  Media

  ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study

  https://www.gsk.com/en-gb/media/press-releases/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-naïve-women-living-with-hiv/

  First published: 18 July 2016

• ViiV Healthcare announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment

  Media

  Headline results were announced in December 2016 and detailed study results are being presented at the annual Conference

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-detailed-positive-phase-iii-results-for-investigational-two-drug-regimen-of-dolutegravir-and-rilpivirine-for-hiv-treatment/

  First published: 13 February 2017

• GSK and University of Nottingham collaborate to create Centre of Excellence for sustainable chemistry

  Media

  GSK & University of Nottingham formalised a collaboration to establish a new laboratory to accommodate the Centre of Excellence

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-university-of-nottingham-collaborate-to-create-centre-of-excellence-for-sustainable-chemistry/

  First published: 26 April 2012

• GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of patients with asthma

  Media

  GlaxoSmithKline plc (GSK) today announced results from the ‘LABA’ (long acting beta2-agonist) safety study, AUSTRI (SAS115359).

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-advair-diskus-achieves-primary-endpoint-in-laba-safety-study-of-patients-with-asthma/

  First published: 27 October 2015

• GSK and Save the Children launch 2015 call for developing country healthcare innovations to reduce child deaths

  Media

  GSK and Save the Children announce the launch of their third annual $1 million Healthcare Innovation Award.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-launch-2015-call-for-developing-country-healthcare-innovations-to-reduce-child-deaths/

  First published: 15 July 2015